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1. Summary
Congenital human cytomegalovirus (HCMV) infection is the leading infectious cause 
of mental retardation, sensorineural deafness and visual impairment. It is mainly related to a 
primary maternal infection. The placenta should be considered the most important site of both 
the protection of the fetus from HCMV infection and the transmission of HCMV from mother 
to fetus.
The transmission of human cytomegalovirus from mother to fetus is a conundrum. 
Neither virologic nor host factors have been identified that are predictive of vertical 
transmission in a given mother-infant pair. It has been shown that healthy HCMV seropositive 
subjects may be simultaneously infected with different HCMV glycoprotein B (gB) 
genotypes. Since little is known about the epidemiology of different HCMV strains in 
maternal to fetal transmission, we characterized the HCMV from maternal, fetal and newborn 
specimens and placentae, and studied the impact of these strains on the clinical outcome of 
the infection. Genotyping on HCMV from congenital infections was carried out on the 
assumption that the envelope gB may influence the outcome of prenatal infection. Sixty-three 
pregnant women were included in the study: 40 pregnant women whose fetuses were strongly 
suspected of having viral infection, and 23 women with normal pregnancies, from whom 
amniotic fluid was taken for fetal karyotype assessment. The amniotic fluid, placenta, 
maternal and fetal peripheral leukocytes, serum and urine of the newborns were examined for 
HCMV DNA by a nested polymerase chain reaction (nPCR), and the gB genotype was 
determined by restriction fragment length polymorphism (RFLP). HCMV DNA was detected 
in 12 cases in which the fetuses were suspected of having a viral infection and in 3 of the 
normal pregnancies. All the HCMV DNAs had identical genotype, gBl. In the matched 
samples from mother-infant pairs the genotype of HCMV was similar. None of the mothers 
were infected with more than one gB genotype. The clinical outcomes of the congenital 
infections varied. Our data indicate a predominance of the gBl genotype in congenital 
infection, which could reflect the infection type of the study population. The clinical outcome 
of these pregnancies, however, cannot be predicted on the basis of the involvement of this 
genotype.
Seroimmunity to human cytomegalovirus prior to conception provides substantial 
protection against symptomatic infection of a newborn. The most important parameter for 
neutralization of HCMV is the titer of neutralizing antibodies. The major target for them on 
HCMV is the envelope glycoprotein B. The present study was undertaken to find out if 
pregnant women and their matched controls differ with regards to the prevalence of IgG and 
neutralizing antibodies specific to Towne (gB type 1) and to AD 169 (gB type 2) strains of 
HCMV. Furthermore we measured the capacity of neutralizing antibodies in the serum or in 
the plasma by a microneutralization assay. The study group consisted of 90 women (age 18- 
45 years); 30 women with normal pregnancy, 30 women with fetus suspected of having viral 
infection and 30 age-matched femal blood donors, had not yet been pregnant. Strain-specific 
antibodies against strains Towne (gBl) and AD169 (gB2) of HCMV were detected by 
ELISAs and microneutralization assay. The avidity of IgG was measured by a HCMV IgG 
avidity test.
The prevalence of Towne- and AD169-specific IgG of pregnant women proved to be 
82.5% and 78.5%, respectively. Towne-specific IgG was found in 72% of blood donors. No 
detectable IgM antibodies were found in any of the pregnant women. The results showed 
prevalence of neutralizing antibodies in pregnant women 80% and 83.5% to Towne and 
AD 169, respectively. Neutralizing antibodies were detected in 73% of blood donors against 
both strains of HCMV. No significant differences were found between the neutralizing 
antibody titers to Towne and AD 169 in blood donors. The neutralizing capacity against both 
strains of HCMV was more effective in pregnant women with normal pregnancy than in 
blood donors. However, the neutralizing capacity to Towne strain was significantly lower 
than to AD 169 in pregnant women with fetus suspected of having viral infection. The 
difference ranged from 4-fold to 16-fold in that neutralization titer.
According to the results of the IgG-avidity test most of the congenital infections 
originated from recurrent maternal infection.
Our data demonstrate significant differences in the prevalence and level of HCMV 
strain-specific neutralizing antibodies in pregnant women and age-matched female blood 
donors, which might have important implication for understanding of the pathogenesis of 
congenital HCMV infection and for development of anti-HCMV immunotherapy and vaccine.
2. Introduction
Human cytomegalovirus (HCMV) is a member of the Herpesviridae family. All 
known strains of HCMV are genetically homologous, but none seem to be genetically 
identical unless they are obtained from epidemiologically related cases [1,2], The sources of 
HCMV include urine, oropharyngeal, cervical and vaginal secretions, semen, breast milk, 
tears, blood products, and allografts [3-7], HCMV is not higly contagious: spreading of the 
infection appears to require close or intimate contact of either a nonsexual or a sexual nature 
with another person who is shedding the virus in the bodily secretions. It can also be 
transmitted vertically, from mother to fetus. Infection with HCMV can be classified as either 
primary or recurrent. Studies on the age-related prevalence of infection with HCMV suggest 
that there may be three periods with particularly high rates of acquisition of the virus: early 
childhood, adolescence and the childbearing years. The prevalence of HCMV infection in the 
normal population varies widely between 40% and 90%, depending on the race, the gender, 
the age and the socioeconomic status [8]. HCMV is more prevalent among people in low 
socioeconomic brackets living in crowded conditions and in people living in undeveloped 
countries, with 80% of 3-year-old children and most adults in such groups being infected with 
HCMV [9, 10], In Hungary, the seroprevalence of HCMV at the age of 10 years is 72%, 
which increases to 96% by the age of 50 [11]. After primary infection, the virus becomes 
latent, residing in the host throughout life. It is reactivated periodically during episodes of 
mild immunosuppression caused by intercurrent infection, pregnancy or stress. Recurrent 
infections are fairly common [12]. Intermittent excretion of the virus can be anticipated in a 
significant proportion of seropositive adults. Reinfection by a new strain of HCMV has been 
documented in immunocompromised individuals, women attending a clinic for sexually 
transmitted diseases and healthy children attending a day-care center [13-16].
Human cytomegalovirus rarely causes symptoms in an immunocompetent host, and 
these can be nonspecific symptoms, such as malaise, fever, sweats, aching muscles, atypical 
lymphocytosis and mild hepatitis during the self-limiting primary infection [17]. However, it 
can give rise to serious disease in an immunodeficient person, such as those with AIDS or 
neonates, and especially premature babies [12]. Reactivation is asymptomatic, except in 
severely immunocompromised individuals.
Human cytomegalovirus is the leading cause of congenital infection in developed 
countries, occurring in 0.3-2% of all live births [18]. To date very little research has been 
carried out on the natural history of intrauterine HCMV infection. In most cases the mother’s 
infection was inapparent. The prevalence displays a specific geographical pattern: it is 0.9% 
in Hungary [12, 19]. Primary HCMV infection in adolescent females (aged 14-20) is mainly 
acquired by oral/sexual contact with saliva, genital secretions and semen, particularly in those 
of lower socioeconomic groups who change sex partners frequently [20, 21]. Women aged 
>25 years from the middle and upper socioeconomic classes, though not exempt from sexual 
promiscuity, may acquire infection predominantly by close contact with asymptomatic infants 
and toddlers who excrete HCMV in their saliva and urine [22, 23]. HCMV-seronegative 
women who work with children in day-care have an occupational risk of acquiring HCMV 
[24]. Fomites may also play a role in the transmission because HCMV has been shown to 
remain infective for hours on plastic surfaces [25]. This underlines the increased risk of 
acquiring HCMV infection to seronegative women or women planning pregnancy who are 
working in a child day-care setting. HCMV may also be transmitted and produce a congenital 
infection if a pregnant women or her fetus receives a blood product transfusion from a 
HCMV-seropositive donor.
Recurrent infections are common in pregnant women, and especially in a highly 
immune population, as estimated by the rate of congenital infection [12]. The most frequent 
mechanism for recurrent infection during pregnancy seems to be the reactivation of latent 
virus. However, the possibility of reinfection by HCMV strains other than the original 
infecting strain, particularly in women with multiple sexual partners, has been demonstrated 
by restriction enzyme analysis [26]. Recurrent infection occurs most frequently in the late 
second and third trimesters in seropositive women, when a marked transient depression of 
HCMV-specific cellular immunity can be demonstrated.
It has been reported that more than 10-15% of newborns infected congenitally are 
symptomatic at birth, and that 10-15% of the asymptomatic infected infants will develop 
long-term neurological sequelae, such as mental retardation, deafness, and visual impairment. 
This makes HCMV the leading infectious cause of central nervous system damage in children 
[27, 28]. Transmission of HCMV from mother to fetus can occur throughout gestation, and 
infection during the first 16 weeks of pregnancy has been associated with a higher incidence
of fetal damage [29, 30]. HCMV can also be transmitted to the fetus when primary maternal 
infection occurs before conception, but data are not available on the consequences for the 
newborn under these circumstances. Congenital HCMV infection can be a result of either 
exogenous or endogenous maternal infection. While exogenous infection can be primary or 
nonprimary, as observed in both seronegative and seropositive women, endogenous infection 
is a consequence of the reactivation of latent virus. Primary infection in the mother has a 
much greater clinical impact on the fetus than recurrent infection or exogenous reinfection. 
Primary infection with HCMV during pregnancy occurs in 0.7-4.1% of pregnancies, with a 
mean reported transmission rate to the fetus of 40% [31-33, 18, 34]. In contrast, the 
transmission rate during recurrent infection is much lower (1-2.2%) [31, 35].
HCMV is thought to be is transmitted when infected leukocytes cross the placental 
barrier to reach the fetal circulation via the umbilical cord vessels [36, 37], Other routes may 
also be accessible to viral transmission. Even if in vitro data do not substantiate this 
hypothesis [38], one possibility is that the virus may first infect placental tissues and later 
amniotic cells. Consequently, infected amniotic cells would be ingested by the fetus, after 
which the virus could replicate in the oropharynx and invade the fetal circulation to reach 
target organs. The tubular epithelium within the kidney appears to be a major site of viral 
replication. By either mechanism of infection, the fetus would excrete HCMV via the urine 
into the amniotic fluid. The amniotic fluid therefore seems a logical choice of body fluid for 
the prenatal diagnosis of HCMV transmission [39-45]. In live-bom neonates, demonstration 
of the vims in the urine within the first 3 weeks of life is an indication of congenital infection. 
This can be done by tissue culture or molecular methods.
To date, there is insufficient evidence to predict the consequences of HCMV infection 
of pregnant women, and the question of whether an infected fetus is to be damaged therefore 
remains unanswered.
Virological factor
HCMV glycoprotein B is the major envelope glycoprotein of HCMV and it is encoded 
by UL55 gene. HCMV gB has been implicated in host cell entry, cell-to-cell viral 
transmission and fusion of infected cells in addition to being an important target for both
antibody- and cell-mediated immune responses [46-48]. HCMV gB is expressed as a 
precursor molecule that is glycosylated and then cleaved at codon 461 to form a disulfide- 
linked complex of gp55 and gpll6  [49]. Chou and Dennison devised a method of HCMV 
genotyping based on the gB nucleotide sequence that encodes a variable region encompassing 
the protease cleavage site [50]. They found that there were Hinfl and Rsal restriction sites 
between nucleotides 1344 and 1440. Amplification of this region using the polymerase chain 
reaction (PCR) followed by restriction analysis demonstrated the existence of four different 
genotypes of gB [50], Since gB has been implicated in host cell penetration, it is possible that 
the four types differ with respect to tissue tropism and virulence.
In recent years, several studies have suggested that HCMV strains with different gB 
genotypes are associated with different clinical outcomes of HCMV infection, as in bone 
marrow transplant recipients and in patients with acquired immunodeficiency syndrome 
(AIDS) and HCMV retinitis [51, 52], In contrast, no such correlation was found in renal 
transplant patients [53, 54], It remains unclear whether certain gB genotypes are associated 
with an increased frequency of disease.
Immunological factors
The humoral immune response is an important defense mechanism against human 
CMV. Unlike preconceptional immunity against rubella or toxoplasmosis, preconceptional 
immunity to HCMV provides only partial protection from intrauterine transmission of the 
virus. [55, 34, 35]. The level of HCMV-specific immunity among women of childbearing age 
varies widely among different populations. Seropositive rates in young women in the United 
States and Western Europe range from less than 50 to 85% [56, 57]. In contrast, in the Ivory 
Cost, Japan and Chile, the rate of seropositivity by the end of the second decade of life is 
greater than 90% [58-60].
Those infants who are congenitally infected with HCMV are mainly delivered from 
mothers having the first contact with HCMV or having reactivation during pregnancy. 
Between 0.7-4% of seronegative women are infected during pregnancy and it is known that 
pregnancy itself is not a risk factor for the infection [61]. This recognition has led to several 
studies to examine the possible factors and complex mechanisms that can determine the
pathogenesis of the infection during pregnancy. To come closer to this problem pregnant 
women must be divided into two groups concerning the pregnancy serological status. 
Congenital infection of the infant is most common among those circumstances when the 
mother is seronegative for HCMV before pregnancy and acquire the infection near conception 
or during the first 16 weeks of pregnancy. In these cases there are no maternal antibodies to 
bind to the virus therefore the risk of transmisssion is higher. In those women having 
recurrent infection, in the presence of specific immunity the transmisssion rate is 
approximately 1%, even when the transmission occurs, it is linked to less virulent outcome 
[62]. These infants are usually asymptomatic at birth and develop normally, although 90% of 
them shed the virus in urine for several months to years after birth. Approximatelly 10% of 
the infants will have hearing loss as the only manifestation of the disease [63].
Fowler et. al. reported that the transmission rate is 1.2% and 12.9% in seropositive and 
seronegative women, respectively, indicating that the preconceptional maternal immunity is 
protective against congenital infection, decreasing the risk by 90% [35]. However it is 
unknown why some women, even with recurrent infection and high levels of antibodies 
transmit the virus to the fetus, while others without antibodies during primary infection do not 
[64], The transmission rate during trimesters is approximately the same but the outcome is 
different [63]. Only those infants have severe neurological disorders acquiring the infection 
near conception or during the first trimester.
Determination of the background immunity against HCMV is a key point concerning 
the outcome of the pregnancy and the possible infection of the fetus. The detection of 
antibodies against HCMV is clearly the indicator of infection. If the titer of IgG persists and 
do not show elevation, the individual is said to be seropositive and experienced the infection 
sometime in the past [65]. If the titer of IgG shows at least four-fold elevation or IgM is 
detectable in previously IgG-positive individuals, it suggests reactivation. Primary infection 
may also be documented through the detection of HCMV-specific IgG and IgM, although 
approximately 10% of individuals with primary infection will have negative IgM titer. 
Approximately 10% of women with recurrent HCMV infection also have positive antibody 
titer. IgM antibody may persist for up to 18 months after primary infections [63].
A reliable serological procedure to identify primary infection is determination of IgG 
avidity. The aim of the test is to examine whether the virus-specific antibodies are matured or
not. In the early stage of infection the existing antibodies do not bind to viral antigens exactly, 
but later by the activation of immunological response the antigen-specific antibodies are 
selected. A low IgG avidity is a marker of primary HCMV infection for 18-20 weeks after 
onset of symptoms in immunocompetent host, a high avidity is related to infection in the past 
[62], In Figure 1. there are proposed schemes for diagnosis of pregnant women, according to 
their serological status for cytomegalovirus (62).
Figure 1:
Proposed schemes for diagnosis o f pregnant women, according to their serological status for  
cytomegalovirus (CMV): seropositive for CMV before conception; seronegative for CMV before 
conception, and unknown pre-conception serological status.
Detection of HCMV-specific IgG antibodies does not mean that they have neutralizing 
activity. The major target of neutralizing antibodies is the envelope glycoprotein B by which 
the virus can be classified into four genotypes (gB 1-4), as described above [50]. Neutralizing 
antibodies first appear approximately 15 weeks after acute infection [8], It means that those 
antibodies detected earlier by very sensitive methods such as ELISAs are produced against 
nonglycosilated proteins which appear earlier and they have no neutralizing activity. This fact 
could explain the discrepancy between the different results of ELISAs and neutralization 
assays carried out in the early stage of acute infection.
Aims
The present study was designed to address the following aims:
Aim 1. To determine the distribution of the HCMV gB genotypes in congenital infections and 
to investigate the relationship between the gB genotype and the outcomes of congenital 
HCMV infections.
Aim 2. To examine the HCMV strain-specific serological status of pregnant women and age- 
matched blood donors and to find correlation between the levels of HCMV strain-specific 
antibodies and congenital infection.
3. Materials and Methods
Patients and samples
Sixty-three pregnant women who were referred to the Department of Gynecology and 
Obstetrics of the University of Szeged between January 1996 and August 1998 were included 
in the study. In 40 pregnancies (gestational age: 27±8.4 weeks), the fetuses or newborn babies 
were strongly suspected of having viral infections (suspected group). The suspicion of virus 
infection arose in consequence of the detection of an abnormality by the ultrasound scan, such 
as intrauterine growth retardation (IUGR), nonimmune hydrops fetalis, ascites, hydrothorax, 
hydrocephaly, microcephaly, spina bifida, hepatomegaly, hyperechogenic bowel, or a heart or 
kidney anomaly. Those cases of spontaneous abortion or premature delivery that involved a 
suspicion of viral infection were also included. Twenty-three women at no risk of fetal 
HCMV transmission, but from whom amniotic fluid was taken for fetal karyotype assessment 
constituted the control group (gestational age: 17.3±1.8 weeks).
A total of 60 amniotic fluid samples were examined; 37 of these were from the 
suspected group, and 23 from the healthy pregnant women. From 8 pregnancies, fetal (n=4) 
and newborn (n=6) blood samples were obtained. A total of 12 urine samples from 6 
newborns were also included in the study. The urine samples of infants suspected of having 
viral infection were examined for HCMV DNA within the first 2 weeks of life. We also 
detected HCMV DNA from blood samples of the mothers where available, and from placenta 
samples from 6 pregnancies from the suspected group.
Ethical approval for this study was granted by the Human Investigation Review Board 
of the University of Szeged.
Processing o f specimens
Amniotic fluid and urine samples were aliquoted into Eppendorf tubes or centrifuged 
at 300 g for 5 min, and the supernatant and sediment were stored at -70°C until they were 
processed. Peripheral blood was collected in anticoagulant-containing vacuetta tubes 
(Greiner, Germany). Peripheral blood leukocytes were isolated by centrifugation of whole
blood at 300 g for 5 min, with subsequent lysis of the erythrocytes. The peripheral blood 
leukocytes were pelleted, washed 3 times with phosphate-buffered saline (PBS), pH 7.4, and 
quantitated. Peripheral blood leukocytes suspensions were adjusted with PBS to a 
concentration of 106 peripheral blood leukocytes per ml. Aliquots of 5xl05 peripheral blood 
leukocytes were centrifuged at 550 g for 5 min. The supernatant was discarded and the cells 
were stored at -70°C until use. Placenta samples were stored at -70°C until they were 
processed.
DNA preparation
Aliquots of 5xl05 peripheral blood leukocytes were resuspended in 200 pi of PBS. 
HCMV DNA was individually extracted from at least 3 aliquots of amniotic fluid, urine, 
peripheral blood leukocytes and placentas (200 pi each), using the High Pure Viral Nucleic 
Acid Kit (Boehringer Mannheim GmbH, Indianapolis, IN, USA) according to the 
manufacturer’s instructions, and was resuspended in 50 pi of nuclease-free distilled H2O.
Polymerase chain reaction amplification of gB gene and restriction analysis
A region of high peptide variability in the gB gene was amplified. To improve the 
sensitivity and to overcome sequence variation between strains, a nested PCR was used. 
Primers for amplification were selected from the published gB sequences of HCMV strain 
AD169 [50], The primers were as follows: outer primers: gB 1246, 5’-GGAAACGTGT 
CCGTCTTTGA; gB 1724, 5’-GAGTAGCAGCGTCCTGGCGA; internal primers: gB 1319, 
5 ’ -GG A ACT GGAAC GTTT GGC; gB 1604, 5 ’ -GAAACGCGCGGCAATCGG. The first 
round of amplification was carried out in a total volume of 50 pi, using 5 pi of DNA extract, 
PCR mix I, consisting of lOx Reaction Buffer (Pharmacia Biotech, Uppsala, Sweden), sterile 
H2O, supplemented with 0.4 pM of each oligonucleotide primer; and PCR mix II, consisting 
of 200 pM of each of the four dNTPs, 1.25 U of Taq polymerase (Pharmacia Biotech, 
Uppsala, Sweden), lOx Reaction Buffer, distilled H2O. The second round of amplification 
was carried out in a total volume of 50 pi, 3 pi of the first-round amplification product being 
added to 25 pi of PCR mix I. 20 pi of PCR mix II was added to each sample. The samples
were covered with mineral oil (Sigma, Deisenhofen, Germany), denatured (95°C, 300 sec), 
and amplified in 35 cycles (95°C, 30 sec; 55°C, 40 sec; 72°C, 60 sec). Amplification products 
(293-296 bp, the size varying with the strain) were analyzed by electrophoresis in a 2% 
agarose gel (BRL, Gaithersburg, Germany) stained with 5 pi of 10 mg/ml ethidium bromide 
(Serva Feinbiochemica, Heidelberg, Germany) and subjected to restriction analysis by using 
Hinfi and Rsal (Promega, Madison, WI, USA) as previously described [50]. Digested DNA 
was analyzed in a 3% agarose gel (Nu Sieve 3:1, FMC Bio Products, Rockland, ME, USA). 
Four distinct gB genotypes can be identified via the different lengths of restriction fragments 
(36-239 bp) [50],
DNA from the Towne HCMV strain (gB genotype 1) was used as a positive control, 
and a sample without any DNA as a negative control.
Immunological methods
Study population and clinical specimen
Pregnant women (n=60) who were referred to the Department of Gynecology and 
Obstetrics of the University of Szeged between January 1996 and August 1998 were included 
in the study; 30 pregnant women (mean age: 28.7±6.6 years) with normal pregnancies 
(gestational age: 29.7±11.3 weeks), and 30 women (mean age: 27.4+4.6 years) with fetuses 
suspected of having viral infection (gestational age: 27.8+8.7 weeks). The study population 
consisted also of 30 age-matched blood donors, as controls (mean age: 26.9+7 years) with no 
history of pregnancy (Table 1. and 2.). Plasma or serum samples of women were collected 
and stored at -20°C until examination.
Cell culture and virus
Human embryo fibroblast (MRC-5) cells were obtained from the Wistar Institute, 
Philadelphia, PA, USA. Cells were propagated in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS) (Gibco Life Technologies Inc., Paisley, Scotland), penicillin (100 U/ml),
streptomycin (100 pg/ml) in 75 cm2 tissue culture flasks (Coming Costar Corporation, 
Oneonta, NY, USA) at 37°C in a humidified chamber with 5% CO2 and passaged weekly.
Towne (gBl) and AD 169 (gB2) laboratory strains of HCMV were obtained from the 
Wistar Institute, Philadelphia, PA, USA, and propagated in MRC-5 cells by standard 
procedure and stored in 1 ml aliquots in liquid nitrogen [66]. The infectivity of virus was 
determined by plaque assay [67].
Table 1. Age distribution o f women with normal pregnancy and with fetuses 
suspected o f having viral infection and blood donors.
Women
Age (year)
18-24 25-29 >30 Mean ± SD*
With normal 
pregnancy 9 8 13 28.7 ±6.6
With fetus 
suspected of 
having viral 
infection
10 11 9 27.4 ±4.6
Blood
donors 13 9 8 26.9 ±7.0
* standard deviation
Table 2. Gestational age o f pregnancies at collection o f specimens.
Pregnancies
Gestational age (week)
<14 15-28 >29 Mean ± SD*
Normal 0 13 17 29.7 ± 11.3
Fetus suspected 
of having viral 
infection
3 10 17 27.8 ± 8.7
* standard deviation
Enzyme-linked immunosorbent assay
All samples were screened by two different types of ELIS As.
Type 1:
ELISA (in house) for detecting antibodies to Towne strain of HCMV were 
performed as described by Gonczol et al [68]. A preparation of semipurified Towne strain of 
HCMV was used as coating antigen in assays to detect Towne strain-specific serum 
antibody. After coating the wells, plates were blocked with PBS containing Tween 20 
(0.05%, v/v) and skim milk (1% w/v) for one hour. After discarding the blocking solution the 
plates were washed three times with PBS containing Tween 20. For antibody testing, plasma 
or serum samples and horseradish peroxidase HRP-labeled anti-human IgG (Sigma) were 
diluted in blocking buffer containing skim milk (0.4%) and incubated sequentially on the 
plates. After washing, bound peroxidase was detected by adding substrate (0.1 M citrate 
buffer (pH 4.5) containing hydrogen peroxide (0.012%, v/v) and 0-phenylene-diamine 1 
mg/ml) for 10 min, at which point the reaction was stopped with 4 M sulfuric acid. The 
optical density (OD) at 490 nm was read with a microplate reader (Stat Fax-2100, 
Awaraness Technology Inc. Palm City, FL, USA). The cutoff value for antibody positivity 
was defined as the mean OD of five seronegative sera plus 3SD.
Type 2:
Commercially available ELISA kits (Enzygnost Anti-CMV/IgG and Enzygnost Anti- 
CMV/IgM kits, Dade Behring Marburg GmbH, Marburg, Germany) were used. The ELIS As 
were manually performed traditional indirect assays in which microtiter plate wells were 
coated with purified HCMV (strain AD 169) and the results were interpreted according to 
the manufacturer's recommendations. Serum samples were pretreated by rheumatoid 
factor adsorbent prior to testing with ELISA for CMV-IgM. Serum samples were diluted 
in the respective test buffers and incubated in a humidified chamber for 60 min at 37°C. The 
plate was washed with washing buffer 3 times. Then 100 pi of horseradish peroxidase 
conjugated goat anti-human IgM or IgG was added. After 60 min incubation at 37°C the 
plate was washed 3 times and 100 pi of Chromogen TMB was added into all wells and 
incubated for 30 min at room temperature. 100 pi of stopping solution blocked the
reaction. The evaluation was carried out within 60 min. The assay wavelength to be used was 
450 nm.
Avidity of IgG
The determination of IgG antibody avidity was carried out by the urea determination 
procedure using a kit recently made available (Cytomegalovirus IgG Avidity EIA WELL, 
produced by RADIM, Rome, Italy). The coating-antigen is characterized by an HCMV 
strain AD 169. The test is based on the difference between the absorbance values due to 
antibody binding in the absence and in the presence of 4.5 M urea. The test was run and 
results were interpreted as it is suggested by the manufacturer. Briefly, 10 pi of sera 
were diluted in 3 ml sample diluent. Control samples of high and low avidity indices 
were included in each test run. 100 pi of dilution of serum to be tested were added to 
the antigen-coated wells. After an hour incubation in a humidified chamber at 37°C the plate 
was washed four times with 350 pi of washing solution (PBS Tweemdistilled water = 
1:20). After discarding the washing solution 100 pi sample diluent (into the odd wells) and 
100 pi of dissociating reagent were added into the even wells and incubated for 30 
min at 37°C. The plate was washed 4 times and 100 pi of enzyme tracer was added 
into all wells and incubated for 30 min at 37°C. After washing four times 100 pi of 
freshly prepared substrate solution was added into all wells and incubated for 10 min at 
37°C. After incubation 100 pi of blocking reagent was pipetted into all wells. The OD at 
450 nm was read with a bichromatic spectrophotometer within 60 minutes. CMV- 
specific IgG avidity index (AI) expressed as follows: percentage of AI = (absorbance 
results of CMV for well with urea wash/absorbance results of CMV for well without 
urea wash) x 100. An AI lower than 35% was considered low and indicates acute 
primary infection, index of 35-45% is considered borderline and an avidity index higher 
than 45% was considered high indicating past infection.
Microneutralization assay
Neutralizing antibodies to Towne and ADI69 strains of HCMV were measured by a 
rapid microneutralization assay. HCMV neutralization test was carried out as described by 
Gonczol et. al. [69], Briefly, 96-well, sterile, flat bottomed culture plates were filled with 60 
pi RPMI 1640 supplemented with 5% fetal bovine serum (FBS), penicillin (100 U/ml), 
streptomycin (100 pg/ml) except the first line wells. The first line was filled with 90 pi RPMI 
1640 and equal volume of plasma or serum samples (30 pi) were added to each and serial 
two-fold dilutions were made. Control wells received culture medium only. Then the virus 
and complement suspension was added. Each well contained 5000 plaque forming unit (PFU) 
of the virus. After an hour long incubation at 37°C, 60 pi cell suspension (3-5x104 cell/well) 
was added to each well and incubated for additional 48 hours. The results were determined 
with the help of positive and negative controls in which the cells and the cytopathic effect 
(CPE) of the virus can be evaluated. The reciprocals of the highest dilution of plasma or 
serum that inhibited 90% of the viral CPE were reported as the neutralizing titer.
Statistical analysis
Owing to the non-normal distribution of neutralizing antibody titers nonparametric test 
were suitable. For the global analysis of data the Kruskal-Wallis nonparametric ANOVA test 
was used. Pairwise comparisons were tested using the Mann-Whitney U-test. When multiple 
comparisons were performed, we applied Bonferroni correction. Two-tailed p values are 
given throughout the test. Two-tailed p values of <0.05 were considered to be significant. All 
the calculations were performed on a SPSS 9.0 software.
4. Results
Aim 1. To determine the distribution o f the HCMV gB genotypes in congenital infections and 
to investigate the relationship between the gB genotype and the outcomes o f congenital 
HCMV infections.
Forty pregnancies in which the fetuses were suspected of having a viral infection and 
23 normal pregnancies were examined for congenital HCMV infection. The presence of 
HCMV DNA was detected by means of a nested PCR specific for the nucleotide region 
between bases 1319 and 1604 of the gB gene in the samples of amniotic fluid, fetal or 
newborn blood, blood of the mother, urine of the fetus or newborn, and placenta. HCMV was 
found in 12 (30%) of the pregnancies in the suspected group, and in the amniotic fluid 
samples from 3 women with normal pregnancies (13%) (Table 3.).
Table 3. Congenital HCMV Infection Detected by PCR.
Pregnancies Gestational age (weeks)
HCMV DNA
Positive Negative
Fetus suspected of having 
viral infection* 27±8.4 12 28
Normal 17.3±1.8 3 20
"Intrauterine growth retardation, nonimmune hydrops fetalis, hydrocephaly, microcephaly, 
spina bifida, hyperechogenic bowel, heart or kidney anomaly
Genotyping of HCMV DNA from the amniotic fluid, urine and peripheral blood 
leukocyte samples was undertaken by restriction fragment length polymorphism (RFLP). All 
the HCMV DNA had identical genotype, gBl. The gB restriction endonuclease digest 
patterns of amplimers from the Towne strain (gB genotype 1) and that from one of the 
amniotic fluid samples in the suspected group are shown in Figure 2.
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Figure 2. Restriction patterns o f gB PCR products from two HCMV DNA.
A: DNA from Towne strain. B: HCMV DNA from case 11. Lanes 1, 2, PCR-amplified part of gB cut with 
Hinf 1 and Rsal, respectively; lane 3, undigested amplimers. Mw, molecular weight markers.
In the matched samples from the mother-infant pairs, the HCMV genotypes were 
similar. The restriction enzyme patterns of the gB PCR products from the mother’s blood, the 
amniotic fluid and the placenta in case 11 are shown in Figure 3. None of the mothers were 
infected with more than one gB genotype.
Information concerning the infected fetal and neonatal outcomes was obtained directly 
when the mothers had terminated the pregnancies or given birth. The infection status of the 
neonates was classified on the basis of the detection of viral DNA within 2 weeks after birth. 
The infected neonates were further classified as having symptomatic or asymptomatic 
infection.
Figure 3. Restriction patterns o f gB PCR products from mother’s blood, amniotic fluid and placenta 
Case 11. A: mother’s blood, B: amniotic fluid, C: placenta; Lanes 1 and 2 of each panel represent the 
PCR-amplified part of gB cut with Hinfl and Rsal, respectively; Lane 3 of each panel shows the 
undigested amplimers. Mw, molecular weight markers.
The clinical outcomes of the pregnancies of the 12 women in the suspected group 
whose fetuses or newborns proved to be infected in utero are shown in Table 4. Congenital 
HCMV infection was observed in 10 fetuses and in 6 neonates (4 of the pregnancies had 
twins). The ultrasonographic findings were abnormal in 9 pregnancies involving 11 fetuses. 
Six of the 9 cases (cases 1, 2, 6, 8, 9, and 10) were detected between 31 and 38 weeks 
gestation. The newborns (n=7) were HCMV-infected, 3 without symptoms and 4 with 
symptoms. Of the 3 remaining cases, which were between 19 and 24 weeks gestation, case 5 
was a twin bichorionic biamniotic pregnancy. At 21 weeks gestation, the ultrasonographic 
scan revealed that one of the twins was anencephalic, and elective abortion was carried out. In 
case 11, the fetus was hydrocephalic; this was detected at 24 weeks of gestation and the 
decision was made to terminate. Necropsy revealed internal hydrocephaly, corpus callosum 
agenesia, cerebellum malformations, and focal lesions in the placenta. In case 12, with 
polycystic kidney, the pregnancy was likewise terminated. In 3 cases (cases 3, 4, and 7), 
ultrasound examinations did not detect any anomalies. The outcomes of these pregnancies 
were spontaneous abortion (case 3) or premature delivery (cases 4 and 7).
The control group consisted of 23 women from whom samples of amniotic fluid were 
taken for fetal karyotype assessment. None of these mothers had any history of infections 
during pregnancy. The ultrasonographic findings were normal. HCMV DNA was found in the 
amniotic fluid samples from 3 of the 23 pregnancies (Table 3).
Table 4. Characteristics and Outcomes o f Pregnancies with gB Genotype 1 HCMV Infection.
HCMV DNA
Case
number
Weeks of 
gestation
Ultrasonographic
findings
Amniotic
fluid
Blood of 
fetus (F) or 
newborn (N)
Urine of 
infant Outcome
1 31 Nonimmune hydrops + + (F) + Symptom-free CMV-infected neonate,
fetalis week 36.*
2 38 Intrauterine growth 
retardation
+ + (N) ND Small for gestational age, CMV- 
infected neonate.
3 21 Twins + ND ND Spontaneous abortion.
4 24 Twins “A”: ND + (N) ND Premature delivery at week 24.*
“B”: ND + (N) +
5 21 Twins ND -(N) + Symptom-free, CMV-infected neonate,
“A”: normal week 36.*
“B”: anencephaly + + (F) ND Selective abortion at week 21.
6 36 Discordant twins “A”: ND ND + Small for gestational age, CMV- 
infected neonate.
“B”: ND ND + Symptom-free CMV-infected neonate.
7 32 Normal + ND ND Premature delivery.
8 35 Hepatomegaly + + (N) + Symptom-free CMV-infected neonate, 
week 39.*
9 31 Spina bifida, + + (N) ND CMV-infected neonate with spina
hyperechogenic bowel, 
microcephaly
bifida and microcephaly, week 41.*
10 34 Nonimmune hydrops 
fetalis
+ + (F) ND Nonimmune hydrops fetalis, week 34.*
11 24 Hydrocephaly + + (F) ND Termination of pregnancy.
12 19 Polycystic kidney + ND ND Termination of pregnancy.
ND, not done; * time of delivery.
Aim 2. To examine the HCMV strain-specific serological status o f pregnant women and age- 
matched blood donors and to find a correlation between the levels o f HCMV strain-specific 
antibodies and congenital infection.
Cytomegalovirus strain-specific humoral immunity was investigated in pregnant 
women and age-matched blood donors by using two laboratory strains of HCMV: 
Towne (gBl) and AD 169 (gB2). The prevalence of strain-specific IgG and of neutralizing 
antibody activity, the level of neutralizing antibodies and the IgG avidity were measured in 
serum and plasma samples. The study group consisted of 30 women with normal 
pregnancies, 30 women with fetuses suspected of having a viral infection and 30 age- 
matched blood donors who had not yet been pregnant (Tables 1. and 2.).
Prevalence of IgG antibodies against strains Towne and ADI 69
The prevalence of IgG antibodies against different strains of HCMV was tested in 
two types of ELISA. Strain-specific antibodies against strain Towne were measured in all 
groups of women involved in this study. A detectable amount of antibodies against strain 
Towne was found in 79% of the women. However, IgG antibodies against Towne were 
exhibited by a higher percentilage of the pregnant women (82.5%) than of the blood 
donors (72%). No difference was observed in the prevalence of Towne-specific IgG 
between the groups of pregnant women (Table 5).
The prevalence of antibodies against strain AD169 was investigated only in the 
pregnant women. Antibodies against this strain were detected in 78.5% of them (Table 5). No 
significant difference was found in the prevalence of these strain-specific antibodies between 
the groups of pregnant women. None of the pregnant women had HCMV-specific 
IgM.
Table 5. Prevalence o f HCMV-specific IgG and IgM tested by different ELISAs.
ELISA (in-house)1 ELISA (Behring)2
Women IgG IgG IgM
No. positive/No. tested (%)
With normal 
pregnancy 23/28 (82) 24/30 (80) 0/30 (0)
With fetus suspected 
of having viral 
infection
25/30 (83) 23/30 (77) 0/30 (0)
Blood donors 21/29 (72) NT3 NT3
'Towne-specific; 2AD 169-specific; 3not tested.
Prevalence of HCMV strain-specific neutralization antibodies
Neutralizing antibodies against strain Towne were detected in 78% of all the women 
investigated (n=90), and 80% of them displayed neutralizing antibody activity against strain 
AD169. 80% of the pregnant women and 73% of the blood donors exhibited neutralizing 
antibodies against strain Towne (Table 6). The prevalence of neutralizing antibodies against 
AD169 was 83.5% and 73% in the pregnant women and in the blood donors, respectively. Thus, 
the levels of prevalence of neutralizing antibodies against the two different strains of HCMV in 
the pregnant women and in the blood donors were very similar. Furthermore, there was no 
difference in the prevalence of neutralizing antibodies against strain Towne between the 
women with normal pregnancies and the women with a fetus suspected of having viral 
infection (80% in each group). There was a moderate difference in the prevalence of 
neutralizing antibodies against AD 169 between the normal and the suspected pregnant group 
(80% and 87%, respectively) (Table 6).
The prevalence of neutralizing antibodies against strain Towne obviously
increased with age (68%, 74% and 95%) in the three different age groups of the pregnant 
women (Figure 4). As even higher tendency was observed as concerns the prevalence of 
neutralizing antibodies against strain AD 169 (74%, 79% and 95%). Such a regularity was 
not detected in the blood donors. The levels of prevalence of neutralizing antibodies 
were similar within the age groups 18-24 and 25-29 years, but there was an obvious 
difference between the pregnant women and the blood donors in the third age group (>29 
years), where the prevalence of Towne-specific neutralizing antibodies was 95% in the 
pregnant women and 75% in the blood donors.
Table 6. Prevalence o f neutralizing antibodies against strains Towne and AD 169 ofHCMV.
Neutralizing antibodies against
Women* Towne AD169
No. positive (%)
With normal pregnancy 24 (80) 24 (80)
With fetuses suspected of 24 (80) 26 (87)having viral infection
Blood donors 22 (73) 22 (73)
*30 women in each group
Strain-specific neutralizing activity
To analyze the levels of neutralizing antibodies to strains of HCMV in the groups of 
pregnant women, two tests were used. With the Kruskal-Wallis test, the difference 
between the means of the neutralizing antibody titers in the groups was very significant: 
p=0.0075.
The Mann-Whitney test too was used to compare the neutralizing antibody 
levels in the two groups. Figure 5 shows the neutralizing activity against strains Towne
(gBl) and AD 169 (gB2) in the blood donors (group 1), the women with normal pregnancies 
(group 2), and the women with fetuses suspected of having a viral infection (group 3).
Figure 4. ¡Variation with age o f neutralizing antibodies against strains 
Towne and AD 169 in pregnant women and blood donors.
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Figure 5. Neutralizing activity against strains Towne (gBl) and ADI69 (gB2) 
in pregnant women and blood donors.
Groups
Neutralizing antibody titers against strains Towne and AD 169
in the group o f  blood donors (1), the women with a normal pregnancy (2) and the 
women with fetuses suspected o f having a viral infection.
The horizontal black lines in the boxes are the medians o f  each group distribution. 
The square boxes contain 50% o f the data centered around the median. The vertical 
lines begin at the 10th percentile and end at the 90th percentile.
Neutralizing activity to strain Towne (gBl)
The neutralizing titers were significantly higher in the pregnant women (group 2 and 3) 
than in the blood donors (group 1) (p=0.04). However, there was a significant difference in 
neutralizing antibody titers only between the blood donors and the women with normal 
pregnancies (p=0.02), i.e. the level of neutralizing antibodies to strain Towne was 
lower in the blood donors. The mean of the neutralizing antibody titers in the women 
with fetuses suspected of having a viral infection was similar to that in the blood donors 
(p=0.2).
Neutralizing activity to strain AD 169 (gB2)
The neutralizing antibody titer specific to strain AD 169, was significantly higher in 
the pregnant women overall than in the blood donors (p=0.02): in the women with a normal 
pregnancy it was higher than in the blood donors (p=0.06, marginally significant), but in the 
group of pregnant women with fetuses suspected of having a viral infection it was 
significantly higher than in the blood donors (p=0.03).
Avidity of HCMV-specific IgG
The avidity of the HCMV-specific IgG antibodies was moderate and high in 4% 
and 96%, respectively, of the pregnant women with fetuses suspected of having a viral 
infection.
HCMV-specific serostatus o f pregnant women with an HCMV-infected fetus
HCMV infection was found in 16 fetuses of 12 pregnant women with fetuses 
suspected of having a viral infection. All these cases involved genotype gBl. At the time 
of detection of the clinical symptoms, neither HCMV-specific IgM nor IgG was found in 
3 of the 12 women (Table 7). In 5 women (cases 1, 5, 6, 9 and 11) the titer of 
neutralizing antibodies against strain Towne was 4-16-fold lower than that against strain 
AD 169 (compared on an individual basis). In the sera of most of the women with a 
normal pregnancy, the titers of neutralizing antibodies against strains Towne and AD 169 
did not differ significantly (equal to or less than 4-fold).
A significant difference in the neutralizing titers against strains Towne and 
AD 169 in the sera of 6 blood donors was observed. These ranged from 4-fold to 8-fold. 
In 5 cases a higher neutralization capacity was found against strain AD 169, while in 1 
case the Towne-specific neutralization capacity was significantly higher.
Table 7. HCMV-specific serostatus o f pregnant women with an HCMV (gBl)-infected fetus.
HCMV-specific
Case
number
Maternal
age
Weeks of 
gestation IgG IgG
Neutralizing antibody 
titer2
(year) Towne AD169 AI1 Towne ADI 69
1 42 31 + + 62.7 16 64
2 25 38 + + 58.8 64 128
3 24 21 + + 38.8 16 32
4 30 25 + + 68.4 32 32
5 26 19 + + 60.6 32 128
6 25 12 + + 59.9 <4 16
7 24 21 - - - <4 <4
8 33 36 + + 62.2 64 64
9 25 32 + + 90.2 64 512
10 27 35 - - - <4 <4
11 24 41 + + 63.3 16 128
12 29 13 - - - <4 <4
1 Avidity index.
2 Reciprocals of the highest dilution of plasma or serum that inhibited 90% of the viral CPE.
L
5. Discussion
The factors that influence the transmission of HCMV to the fetus and mediate fetal 
damage have not been fully established. A preexisting HCMV-specific humoral immune 
response can lessen the deleterious effects on the fetus. However, in contrast with congenital 
rubella or toxoplasmosis, the maternal antibody does not completely protect the fetus [70], 
Thus, although congenital HCMV infection is more likely in a seronegative pregnant woman 
who has a primary HCMV infection during pregnancy, HCMV-infected infants can also be 
bom to women with recurrent disease [71-73]. Symptomatic infection occurs in 5-10% of 
infants infected congenitally, with more than 90% of these children experiencing motor, 
visual, cognitive, or auditory sequelae. The remaining 90% of infants infected congenitally 
will have no obvious signs or symptoms of HCMV, but many will develop a sensorineural 
hearing loss subsequently [27, 74, 75].
Prenatal diagnosis of congenital HCMV infection can be carried out by culturing or 
the PCR to detect the HCMV in the amniotic fluid and to distinguish uninfected from infected 
fetuses. However, the outcome of the infection cannot be predicted [39-45]. HCMV is a virus 
that grows relatively slowly in vitro, and Apperley and Golman has shown that the virus could 
not be detected in the blood circulation until 2 or 3 weeks after the primary infection [76], 
Four to six more weeks are necessary for the virus to contaminate the fetus, proliferate in its 
tissues and finally occur in urinary excretion in amniotic fluid. It, therefore, follows that in 
most cases at least 6 weeks elapse are necessary after the mother’s primary infection before 
HCMV can be in the amniotic fluid. Moreover, it seems that the stage of pregnancy at the 
date of amniocentesis influences the sensitivity of the antenatal diagnosis [77, 78]: when the 
mother’s seroconversion occurs during the first 3-month period, a longer delay may be 
necessary before the viral growth becomes detectable in the fetal compartment.
distribution of the gB genotypes in congenital infections indicate that HCMV strains of 
diverse genotypes can be transmitted vertically, and strains bearing the gBl genotype are 
predominant in different geographical regions of the world [84].
The present group of patients were mainly from the city of Szeged; some of the severe 
cases were from three neighboring counties in south Hungary. The gB RFLP of the HCMV 
DNA from the samples revealed that they were homologous. The dominance of gB genotype 
1 could reflect the infection type of the study population. No data on the overall distribution 
of HCMV gB genotypes for populations other than fetuses and newborns are available in 
Hungary.
In this study, HCMV DNA was found not only in the samples from pregnancies in the 
suspected group, but in 3 of 23 normal pregnancies too. Kyriazopoulou et al. published a 
similar observation: HCMV DNA was detected in the amniotic fluid from 4 of 32 pregnant 
women with normal ultrasonographic findings. These women were HCMV seropositive 
before conception. The preconceptional HCMV serostatus of the women in the current study 
was not known, but at the time of amniocentesis they had HCMV-specific neutralizing 
antibodies. These results draw attention to the fact that fetal HCMV infection is not rare 
among pre-immune women [85].
A previous study demonstrated a correlation between the gB genotype and the severity 
of HCMV disease in bone marrow transplant recipients [51]. The patients who survived 
HCMV infections after bone marrow transplantation were more likely to excrete strains with 
the gBl genotype than were patients who died. Shepp et al. reported that the presence of gB2 
in blood isolates was potentially associated with a greater risk of the development of HCMV 
retinitis in patients with AIDS [52]. Another study found no association between HCMV gB 
genotypes and CMV-related central nervous system disease. The HCMV gB types 1 and 2 
were the HCMV genotypes most frequently found, both in the CSF of AIDS patients with 
CMV-related neurological disease (42.3% and 26.9%, respectively) and in the urine and 
saliva of AIDS patients without CNS disease (42.8% and 23.8%, respectively) [86]. It has 
been reported that there is no correlation between HCMV gB genotypes and CMV disease in 
renal transplant patients [53, 54]. However, another study suggests that HCMV gB genotype 2 
is present most frequently in the same group of patients [87]. The gB genotypes did not 
correlate with the neurodevelopmental outcome of intrauterine infection [83], In Toronto,
k
Canada, Sarcinella et al. found that the distribution of HCMV gB genotypes in liver transplant 
patients was: gBl (25.9%), gB2 (27.6%), gB3 (36.2%), gB4 (3.4%) and four patients (6.9%) 
had mixed infection. Symptomatic CMV disease developed in 43.1% of patients and 44.8% of 
them had acute rejection. The rate of CMV disease and acute graft rejection in patients 
infected with the different HCMV gB genotypes was not significantly different. However, all 
four patients with infection with a mixture of HCMV gB genotypes developed progression to 
CMV disease [88]. Coaquette et al. determined the distribution of HCMV gB genotypes and 
the effect of gB type on clinical outcomes in a cohort of immunocompromised patients, 
including both transplant recipients and nonrecipients. They found that in contrast to patients 
infected with a single gB genotype, patients infected with multiple gB genotypes developed 
progression to CMV disease, had an incresed rate of graft rejection, had higher CMV loads, 
and were significantly more often infected with other herpesviruses. The presence of multiple 
gB genotypes, rather than the presence of a single gB genotype, could be a critical factor 
associated with severe clinical manifestations in immunocompromised patients [89],
Our data clearly indicate the dominance of the gBl genotype in congenital HCMV 
infections in south Hungary. However, the clinical outcome of these pregnancies cannot be 
predicted on the basis of the involvement of this genotype. The diverse clinical findings 
observed in association with the dominance of the gBl genotype of HCMV indicate that the 
gB protein is not the only factor that can influence the virulence of HCMV. The clinical 
outcomes of intrauterine infections may reflect the contribution of host factors such as 
immune defense and/or histocompatibility genes. The roles of other viruses (e.g., human 
herpesvirus 6) or endocrine factors cannot be ruled out.
Previous studies have revealed that a high viral load in the amniotic fluid correlates 
with CMV disease in the fetus and newborn [90-92]. Revello and coworkers examined pp65 
antigenemia, viremia and DNAemia in the peripheral blood leukocytes from newborns bom 
to mother who suffered a primary HCMV infection during pregnancy. Their results indicate 
that the difference in median viral load in newborns with CMV disease versus those with 
asymptomatic infection at birth is similar to the difference in viral load observed in the 
amniotic fluid of a fetus with CMV disease (105 GE/ml) versus one with asymptomatic 
infection [92].
In summary, we were not able to demonstrate significant clinical consequences of 
HCMV gB genotype and outcomes in congenital HCMV infections. HCMV is a complex 
virus and its genome contains over 200 open reading frames, including those that code for 
proteins that help it to evade the immune response and likely many other virulence factors. 
Other envelope glycoproteins encoded by HCMV such as gH and gCII could influence the 
importance of gB in virulence and tissue tropism. Further studies into a combination of 
virulence factors may shed light on the relevance of gB to the development of congenital
HCMV infection.
In the matched samples from the mother-infant pairs, the HCMV genotypes were 
similar. None of the mothers were infected with more than one gB genotype. HCMV strains 
of different genotypes can be transmitted vertically [80-83]. Thus, control of the passage of 
HCMV strains across the placenta probably involves a cascade of regulatory events.
Immunologicalfactors
Humoral immune response represents an important defence eliminating HCMV. 
Therefore it is important to monitorize the level of antibodies in the affected population, 
especially in pregnant women. It is known that maternal antibodies are not fully protective 
against HCMV infection but modify the outcome, even the transmission occurs, in those 
cases when the virus does not cause severe neurological damage. The early determination of 
maternal antibody status could reveal the affected patients having risk for transmission. 
The most widely used procedure to screen maternal antibodies is ELISA because of its 
rapidity, sensitivity and standardized evaluation, although smaller differences can be seen 
comparing the given results.
A mixture of viral epitopes has been shown to be very efficient in the activation of 
producing antibodies, but most of them have no neutralizing activity, therefore it is 
inevitable to investigate the level of neutralizing antibodies. The major target of 
neutralizing antibodies is the envelope glycoprotein B (gBl-4). The neutralizing antibody titer 
cannot be evaluated by other serological methods, only by neutralization assay because 
the correlation of neutralizing antibody titer and the total antibody level is low [93], At least 30
% of sera with high ELISA titer for the whole virus have little or no neutralizing activity.
Several HCMV strains are circulating in the population at the same time. Measuring the 
titers of HCMV strain-specific neutralizing antibodies against different strains respectively, a 
visible difference can be seen. Klein et al. analyzed the extent of HCMV strain-specific 
neutralization capacity of human sera. Nine HCMV strains were examined and they observed 
differences from 8-fold to 60-fold in the neutralization titers against each strains. It was 
concluded that the neutralization capacity of human sera was not influenced by the 
presence of antibodies against noninfectious envelope proteins and it was independent of the 
amount of virus [94].
In some cases this can be the explanation of those congenital infections when the 
maternal immunstatus was positive for HCMV indicating that the mother was infected 
sometime in the past. However, the mother became infected with another strain of HCMV 
during pregnancy. The presenting antibodies were not able to neutralize the new HCMV 
strain therefore the transmission occurred although ELISA showed high level of antibodies.
There are differences in HCMV-specific antibody response between women who 
transmit the virus to their offspring and those who do not, suggesting that neutralizing 
antibodies can modulate HCMV spread to endovascular cytotrophoblast (CT) cells. Women 
with CMV disease, and those with subclinical infection and intrauterine transmission, have a 
more prolonged and enhanced serum antibody response as compared with those who do not 
transmit HCMV in utero [95, 96]. Women who do or do not transmit HCMV can be 
differentiated on the basis of their neutralizing antibody titer. Lower titers are present in 
transmitters versus nontransmitters, suggesting an association between neutralizing antibodies 
and intrauterine transmission. A further characterization of the antibody responses revealed a 
marked difference between the two groups of women in the antibody avidity [95], The avidity 
of an antibody is indicative of its functional affinity for an antigen. During the first few weeks 
following a primary infection, the antibodies display a low avidity for the antigen, but as the 
immune response matures, the antibodies acquire a progressively higher avidity. Both 
neutralizing antibody levels and avidity develop relatively slowly after a primary infection, 
suggesting that the mothers who transmit HCMV are in the early stages of primary infection 
during pregnancy. The failure to produce high-affinity neutralizing antibodies may result in a
greater likelihood of virus dissemination and infection of distant organs, including the 
placenta. This in turn may increase the probality of fetal transmission.
Our study suggests that gB genotype 1 is the dominant HCMV variant associated 
with congenital infection. We attempted to find some correlation between the HCMV 
strain-specific maternal antibodies and the congenital infection and therefore sera of pregnant 
women and age-matched blood donors as controls were screened in strain-specific ELISAs and 
neutralization test. The prevalence of Towne and AD169-specific IgG of pregnant women 
proved to be 82.5% and 78.5%, respectively. Towne-specific IgG was found in 72% of the 
blood donors only.
According to our results 80% and 83.5% of pregnant women had Towne and AD169- 
specific neutralizing antibody, respectively. The pregnant women with fetus suspected of 
having a viral infection had significantly lower specific neutralizing antibody titer to strain 
Towne comparing to the group with normal pregnancy. The neutralizing capacity to strain 
Towne in pregnant women, especially pregnant women with fetus suspected of having a viral 
infection was significantly lower than to AD 169. The difference ranged from 4-16-fold in some 
individuals. Five HCMV infected cases belong to this maternal group, in spite of the high 
level of AD169-specific neutralizing antibodies. Differences in humoral immunity, and 
especially the capacity to neutralize strains of HCMV can be one of the reasons why 
recurrent infection with different strains of HCMV can lead to infection of the fetus in 
women who are seropositive for HCMV.
This study suggests that the HCMV strain-specific neutralizing antibody present in the 
maternal blood could inhibit the transmission of the virus to the fetus. The serological 
determination of strain-specific neutralizing antibodies could be important in judging whether 
a subject is naturally protected against severe CMV disease. Our data demonstrate 
differences in the prevalence and capacity of strain-specific neutralizing antibodies in 
pregnant women and age-matched blood donors, which might have important implication for 
understanding of the pathogenesis of congenital HCMV infection and development of anti- 
HCMV vaccines.
The following o f our results are considered novel:
1. The gBl genotype of HCMV predominates in congenital infections in the south of 
Hungary.
2. The presence of HCMV DNA in amniotic fluid samples from normal pregnancies 
drew attention to the fact that in utero HCMV infection without any negative 
consequence for the fetus is not a rare event.
3. The clinical outcomes of the pregnancies involving infection with the HCMV gBl 
genotype varied. It seems that the gB genotyping of HCMV involved in congenital 
infections cannot be used to predict the clinical outcome of the infection.
4. Only one gB genotype of HCMV can be detected in all specimens from the mother- 
infant pair and the placenta.
5. Differences in the prevalence of HCMV strain-specific IgG and neutralizing 
antibodies can be demonstrated in pregnant women.
6. The prevalence and the neutralizing capacity of the antibodies against different strains 
of HCMV can reveal differences which can explain why recurrent infection with a 
different strain of HCMV can lead to infection of the fetus in women who are 
seropositive for HCMV.
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